PATH | VRL
Menu

Phenotypic and Genotypic Characterization of Meningococcal Carriage and Disease Isolates in Burkina Faso After Mass Vaccination With a Serogroup A Conjugate Vaccine

The conjugate vaccine against serogroup A Neisseria meningitidis, MenAfriVac, was first introduced in mass vaccination campaigns of the 1- to 29-year-olds in Burkina Faso in 2010. This study, published in BMC Infectious Diseases, genetically characterized meningococcal isolates circulating in Burkina Faso before and up to 13 months after this MenAfriVac mass vaccination.

Author: Kristiansen PA, Ba AK, Sanou I, et al.

Published: 2013

» Download file (English)

428 KB PDF (Located at www.biomedcentral.com)

Citation: Kristiansen PA, Ba AK, Sanou I, et al. Phenotypic and Genotypic Characterization of Meningococcal Carriage and Disease Isolates in Burkina Faso After Mass Vaccination With a Serogroup A Conjugate Vaccine. BMC Infectious Diseases. 2013;13(363).

Resource types: Peer-reviewed journal

Diseases/vaccines: Meningococcus

Topics: Disease burden and surveillance, Disease/vaccine specific information

Regions: Africa